{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:08Z","timestamp":1787020748734,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fabry disease (FD) is a rare, progressive disorder caused by pathogenic variants of the\n                      <jats:italic>GLA<\/jats:italic>\n                      gene resulting in the accumulation of toxic metabolites. Pain is a hallmark of FD, and patients often present with heterogeneous pain profiles. This cross-sectional, web-based survey was conducted to characterize pain and pain crises in patients with FD in the United States and explore the effects of sex, disease phenotypes, and treatment on pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 66 participants (mean \u00b1\u2009standard deviation [SD] age: 44.0 \u00b1\u200912.7 years; females: 59.1%) completed the survey. Participants reported experiencing pain in upper (34.8%) and lower (43.9%) extremities several times a day and abdominal pain (31.8%) a few times a week. Overall, participants reported the nature of their pain as triggered (upper extremities: 47.0%; abdomen: 51.5%) or sudden (lower extremities: 57.6%). Female participants reported experiencing pain in upper (46.2%) and lower (48.7%) extremities several times a day and described it as sudden or triggered (48.7%) in upper extremities and sudden (61.5%) in lower extremities. Pain crises were reported in the lower extremities (80.0%), followed by the upper extremities (66.7%) and the abdomen (51.1%), and were often characterized as burning, tingling, or stabbing. A higher proportion of female participants (84.6%) than that of male participants (73.7%) reported pain crises in lower extremities. The duration of pain crises varied from 30\u00a0min to several days for different subgroups depending on sex and FD phenotypes. Most participants (81.0%) reported symptom improvement after 12 months of FD-specific treatment. Participants reported improvement in neuropathic symptoms (burning in hands, 45.9%), with an overall mean (\u00b1\u2009SD) satisfaction score of 7.2 (\u00b1\u20091.7) with agalsidase beta as the most recent medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pain was largely reported to be triggered across all subgroups. Consistent pain profiles were noted in participants across sex and FD phenotypes. Female participants reported pain burden similar to that of male participants, and pain crisis experience was heterogeneous across the subgroups. Most participants reported improvement in symptoms after FD-specific treatment and a high treatment satisfaction score with agalsidase beta.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03812-2","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:05:25Z","timestamp":1750071925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterizing pain in patients with Fabry disease: findings from a web-based cross-sectional survey in the US"],"prefix":"10.1186","volume":"20","author":[{"given":"Eric","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Warsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kupferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronabesh","family":"DasMahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9707-2446","authenticated-orcid":false,"given":"Nicole","family":"Lyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"10","key":"3812_CR1","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/biom12101460","volume":"12","author":"F Amodio","year":"2022","unstructured":"Amodio F, Caiazza M, Monda E, Rubino M, Capodicasa L, Chiosi F, et al. An overview of molecular mechanisms in Fabry disease. Biomolecules. 2022;12(10):1460.","journal-title":"Biomolecules"},{"issue":"1\u20132","key":"3812_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344(1\u20132):5\u201319.","journal-title":"J Neurol Sci"},{"issue":"4","key":"3812_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","volume":"31","author":"B Najafian","year":"2020","unstructured":"Najafian B, T\u00f8ndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31(4):865\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3812_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19\u201327.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3812_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822(2):226\u201332.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3812_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"issue":"11","key":"3812_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"issue":"11","key":"3812_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"issue":"5","key":"3812_CR9","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: A multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3812_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):1\u201349.","journal-title":"Orphanet J Rare Dis"},{"key":"3812_CR11","first-page":"100565","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Robles AR, Costa MA, Pereira O, et al. Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation. Mol Genet Metab Rep. 2020;22:100565.","journal-title":"Mol Genet Metab Rep"},{"key":"3812_CR12","unstructured":"Bokhari SRA, Zulfiqar H, Hariz A. Fabry disease Treasure Island (FL): StatPearls Publishing; 2023 [Updated 2022 Dec 24]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK435996\/. Accessed Nov 12, 2023."},{"issue":"10","key":"3812_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936\u2009+\u2009919G\u2009>\u2009A (IVS4\u2009+\u2009919G\u2009>\u2009A). Hum Mutat. 2009;30(10):1397\u2013405.","journal-title":"Hum Mutat"},{"issue":"3","key":"3812_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","volume":"21","author":"MP Wasserstein","year":"2019","unstructured":"Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, et al. The new York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants. Genet Med. 2019;21(3):631\u201340.","journal-title":"Genet Med"},{"key":"3812_CR15","unstructured":"Prescribing information-Agalsidase beta. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103979s5309lbl.pdf. Accessed Nov 12, 2023."},{"key":"3812_CR16","unstructured":"Prescribing information- Pegunigalsidase alfa. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761161s000lbl.pdf. Accessed Nov 12, 2023."},{"key":"3812_CR17","unstructured":"Prescribing information-Migalastat. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208623lbl.pdf. Accessed Nov 12, 2023."},{"key":"3812_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2377-11-61","volume":"11","author":"AP Burlina","year":"2011","unstructured":"Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.","journal-title":"BMC Neurol"},{"issue":"5","key":"3812_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/j.pain.0000000000002152","volume":"162","author":"AJ Burand Jr","year":"2021","unstructured":"Burand AJ Jr., Stucky CL. Fabry disease pain: patient and preclinical parallels. Pain. 2021;162(5):1305\u201321.","journal-title":"Pain"},{"issue":"4","key":"3812_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1756283X16642936","volume":"9","author":"C Zar-Kessler","year":"2016","unstructured":"Zar-Kessler C, Karaa A, Sims KB, Clarke V, Kuo B. Understanding the Gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Th Adv Gastroenterol. 2016;9(4):626\u201334.","journal-title":"Th Adv Gastroenterol"},{"issue":"5","key":"3812_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17(5):323\u201330.","journal-title":"Genet Med"},{"issue":"10","key":"3812_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N \u00dc\u00e7eyler","year":"2014","unstructured":"\u00dc\u00e7eyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in Fabry disease. Clin J Pain. 2014;30(10):915\u201320.","journal-title":"Clin J Pain"},{"issue":"1","key":"3812_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13023-022-02417-3","volume":"17","author":"L Bashorum","year":"2022","unstructured":"Bashorum L, McCaughey G, Evans O, Humphries AC, Perry R, MacCulloch A. Burden associated with Fabry disease and its treatment in 12\u201315 year olds: results from a European survey. Orphanet J Rare Dis. 2022;17(1):266.","journal-title":"Orphanet J Rare Dis"},{"key":"3812_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.expneurol.2019.113134","volume":"324","author":"V Rickert","year":"2020","unstructured":"Rickert V, Kramer D, Schubert A-L, Sommer C, Wischmeyer E, \u00dc\u00e7eyler N. Globotriaosylceramide-induced reduction of KCa1. 1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. Exp Neurol. 2020;324:113\u201334.","journal-title":"Exp Neurol"},{"issue":"11","key":"3812_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"T Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C, Sch\u00f6nfeld D, Banikazemi M, Hopkin RJ, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med. 2010;12(11):703\u201312.","journal-title":"Genet Med"},{"issue":"7","key":"3812_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568\u201376.","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"3812_CR27","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr. 2004;144(5):S20\u20136.","journal-title":"J Pediatr"},{"issue":"1","key":"3812_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13023-021-01894-2","volume":"16","author":"A Hamed","year":"2021","unstructured":"Hamed A, DasMahapatra P, Lyn N, Gwaltney C, Hopkin RJ. Development of the Fabry disease Patient-Reported outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry disease. Orphanet J Rare Dis. 2021;16(1):285.","journal-title":"Orphanet J Rare Dis"},{"key":"3812_CR29","first-page":"100824","volume":"29","author":"A Hamed","year":"2021","unstructured":"Hamed A, DasMahapatra P, Lyn N, Gwaltney C, Iaconangelo C, Serrano D, et al. Fabry disease Patient-Reported outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease. Mol Genet Metab Rep. 2021;29:100824.","journal-title":"Mol Genet Metab Rep"},{"key":"3812_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1155\/2006\/828964","volume":"11","author":"AL Gibas","year":"2006","unstructured":"Gibas AL, Klatt R, Johnson J, Clarke JTR, Katz J. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag. 2006;11:828\u2013964.","journal-title":"Pain Res Manag"},{"issue":"2","key":"3812_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","volume":"106","author":"M Biegstraaten","year":"2012","unstructured":"Biegstraaten M, Hollak CE, Bakkers M, Faber CG, Aerts JM, van Schaik IN. Small fiber neuropathy in Fabry disease. Mol Genet Metab. 2012;106(2):135\u201341.","journal-title":"Mol Genet Metab"},{"issue":"9259","key":"3812_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(05)71823-7","volume":"357","author":"MM Chowdhury","year":"2001","unstructured":"Chowdhury MM, Holt PJ. Pain in Anderson-Fabry\u2019s disease. Lancet. 2001;357(9259):887.","journal-title":"Lancet"},{"issue":"11","key":"3812_CR33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1531::AID-MUS7>3.0.CO;2-O","volume":"22","author":"LS Ro","year":"1999","unstructured":"Ro LS, Chen ST, Tang LM, Hsu WC, Chang HS, Huang CC. Current perception threshold testing in Fabry\u2019s disease. Muscle Nerve. 1999;22(11):1531\u20137.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3812_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9(1):34\u201345.","journal-title":"Genet Med"},{"issue":"3","key":"3812_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.21606","volume":"41","author":"R Liguori","year":"2010","unstructured":"Liguori R, Di Stasi V, Bugiardini E, Mignani R, Burlina A, Borsini W, et al. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve. 2010;41(3):409\u201312.","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"3812_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","volume":"145","author":"A Torvin M\u00f8ller","year":"2009","unstructured":"Torvin M\u00f8ller A, Winther Bach F, Feldt-Rasmussen U, Rasmussen A, Hasholt L, Lan H, et al. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain. 2009;145(1\u20132):237\u201345.","journal-title":"Pain"},{"issue":"2","key":"3812_CR37","first-page":"61","volume":"106","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg. 2006;106(2):61\u20135.","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"3812_CR38","doi-asserted-by":"publisher","first-page":"e1033","DOI":"10.1097\/PR9.0000000000001033","volume":"7","author":"AA Miclescu","year":"2022","unstructured":"Miclescu AA, Gkatziani P, Granlund P, Butler S, Gordh T. Sex-related differences in experimental pain sensitivity in subjects with painful or painless neuropathy after surgical repair of traumatic nerve injuries. Pain Rep. 2022;7(6):e1033.","journal-title":"Pain Rep"},{"issue":"1","key":"3812_CR39","doi-asserted-by":"publisher","first-page":"2367421","DOI":"10.1080\/26895293.2024.2367421","volume":"17","author":"J Morgan","year":"2024","unstructured":"Morgan J, Magwood K, Smith J, Jenkins MR, McGregor AJ, Quesnelle KM. Sex and gender differences in pain perception and management in clinical settings. All Life. 2024;17(1):2367421.","journal-title":"All Life"},{"issue":"5","key":"3812_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353.","journal-title":"J Med Genet"},{"issue":"2","key":"3812_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3812_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","volume":"35","author":"MG Bouwman","year":"2012","unstructured":"Bouwman MG, Rombach SM, Schenk E, Sweeb A, Wijburg FA, Hollak CE, et al. Prevalence of symptoms in female Fabry disease patients: a case-control survey. J Inherit Metab Dis. 2012;35(5):891\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"3812_CR43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S. Fabry outcome survey European investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"3812_CR44","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand O, Johnson J, Walter J, Atkinson L, Kline G, Frey A, et al. Symptoms and quality of life in patients with Fabry disease: results from an international patient survey. Adv Ther. 2019;36(10):2866\u201380.","journal-title":"Adv Ther"},{"issue":"1","key":"3812_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-020-1307-y","volume":"15","author":"S K\u00f6rver","year":"2020","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CEM, van Schaik IN, Longo MGF, Lima MR, et al. Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain. Orphanet J Rare Dis. 2020;15(1):28.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3812_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-023-02796-1","volume":"18","author":"KM Stepien","year":"2023","unstructured":"Stepien KM, Broomfield A, Cole D, Deegan PB, Forshaw-Hulme S, Hughes D, et al. Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel. Orphanet J Rare Dis. 2023;18(1):203.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03812-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03812-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:02:11Z","timestamp":1750075331000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03812-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03812-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3725282\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants of the study provided electronic consent prior to starting the survey. This study was submitted for institutional review board approval and deemed exempt from review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EW had disclosures with Sanofi, Idorsia, Amicus, Chiesi, Protalix, Walking Fish Therapeutics, Spark Therapeutics, Natera, and DaVita. DL is chair of the North American Fabry Registry Board and provides consultations for Chiesi, Sanofi, and Spark Therapeutics. She is also an investigator\/coordinator in clinical trials sponsored by 4DMT, Amicus, Chiesi, Protalix, Sangamo, Sanofi, and Takeda-Shire. She is also a cofounder of ThinkGenetic, Inc. These activities were monitored and found to be compliant with the conflict-of-interest policies at the Emory University School of Medicine. IW was on an assignment at Sanofi through Integrated Resources at the time of study completion; currently, he is an employee of Evidentia Dental Research, Canada. CB and JJ are the Fabry Support & Information Group employees and provide participant outreach and recruitment support. PD and NL are employees of Sanofi and stockholders in the company. JK was an employee of Sanofi at the time this study was conducted; currently, he is an employee of Moderna.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"308"}}